Published in final edited form as:

Biochemistry. 2013 October 15; 52(41): 7196–7206. doi:10.1021/bi400561e.

Intermonomer Electron Transfer between the *b* Hemes of Heterodimeric Cytochrome *bc*₁

Pascal Lanciano, Bahia Khalfaoui-Hassani, Nur Selamoglu, and Fevzi Daldal*

Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Abstract

The ubihydroquinone:cytochrome *c* oxidoreductase, or cytochrome *bc*₁, is a central component of respiratory and photosynthetic energy transduction pathways in many organisms. It contributes to the generation of membrane potential and proton gradient used for cellular energy (ATP) production. The three-dimensional structures of cytochrome *bc*₁ show a homodimeric organization of its three catalytic subunits. The unusual architecture revived the issue of whether the monomers operate independently or function cooperatively during the catalytic cycle of the enzyme. In recent years, different genetic approaches allowed the successful production of heterodimeric cytochrome *bc*₁ variants and evidenced the occurrence of intermonomer electron transfer between the monomers of this enzyme. Here we used a version of the “two-plasmid” genetic system, also described in the preceding paper (DOI: 10.1021/bi400560p), to study a new heterodimeric mutant variant of cytochrome *bc*₁. The strain producing this heterodimeric variant sustained photosynthetic growth of *Rhodobacter capsulatus* and yielded an active heterodimer. Interestingly, kinetic data showed equilibration of electrons among the four *b* heme cofactors of the heterodimer, via “reverse” intermonomer electron transfer between the *b*_L hemes. Both inactive homodimeric and active heterodimeric cytochrome *bc*₁ variants were purified to homogeneity from the same cells, and purified samples were subjected to mass spectrometry analyses. The data unequivocally supported the idea that the cytochrome *b* subunits carried the expected mutations and their associated epitope tags. Implications of these findings on our interpretation of light-activated transient cytochrome *b* and *c* redox kinetics and the mechanism of function of a dimeric cytochrome *bc*₁ are discussed with respect to the previously proposed heterodimeric Q cycle model.

© XXXX American Chemical Society

*Corresponding Author fdaldal@sas.upenn.edu. Telephone: (215) 898-4394. Fax: (215) 898-8780.

Notes The authors declare no competing financial interest.

Supporting Information: Comprehensive list of peptides relevant to cytochrome *b* positions F144 and H217, wild type, mutations, and related epitope tags detected by nLC-MS/MS analyses, and spectra of relevant peptides (Figure S1), and light-activated cytochrome *c* re-reduction and cytochrome *b* reduction kinetics obtained using membranes from a (cyt *b*-S F144R + cyt *b*-F H217L) heterodimer-producing RecA[−] strain (Figure S2). This material is available free of charge via the Internet at <http://pubs.acs.org>.

The ubiquinone:cytochrome *c* oxidoreductase (also called cytochrome *bc*₁ or complex III) is a multisubunit membrane-bound enzyme that is central to respiratory and photosynthetic energy transduction pathways in various organisms.¹ It converts hydroquinones (QH₂) to quinones (Q), reduces various electron carriers (often cytochromes *c*), and contributes to the formation of the membrane potential and proton gradient that are used for cellular ATP production.^{2,3} In most bacteria, like *Rhodobacter capsulatus*, cytochrome *bc*₁ consists of three universally conserved catalytic subunits: the Fe–S protein, cytochrome *b*, and cytochrome *c*₁.^{4,5} Cytochrome *b* is an integral membrane protein, whereas the Fe–S protein and cytochrome *c*₁ are membrane-anchored by their amino- and carboxyl-terminal helices, respectively. These subunits carry specific cofactors that are essential for enzyme activity. The cofactors are the high-redox midpoint potential (E_m) [2Fe-2S] cluster in the Fe–S protein, the two *b*-type hemes with one low- E_m (*b*_L) and one high- E_m (*b*_H) heme in cytochrome *b*, and the high- E_m *c*-type heme in cytochrome *c*₁.⁶ Available three-dimensional structures of cytochrome *bc*₁ from various organisms depict this enzyme as a symmetrical homodimer with each Fe–S protein spanning both monomers.^{7–9} In addition, the dimer interface between cytochrome *b* subunits brings the low- E_m *b*_L hemes of the two monomers very close to each other (~11 Å). These observations led to the intriguing possibility of intermonomer electron equilibration between the *b* hemes of cytochrome *b* subunits in dimeric cytochrome *bc*₁.

The modified Q cycle used to describe the cytochrome *bc*₁ mechanism of function requires two consecutive Q₀ site-mediated QH₂ oxidations for a complete catalytic cycle.¹⁰ Whether the two consecutive QH₂ oxidations occur only in a given monomer as initially described¹¹ or whether they alternate between the two Q₀ sites of a dimeric enzyme is unknown. Over the years, several groups, including our own, provided experimental data that could be interpreted in different ways,^{12–15} especially in light of the symmetrical homodimeric cytochrome *bc*₁ structures. Because of the inherent symmetry, the intramonomer versus intermonomer electron transfers between the *b* heme cofactors of cytochrome *bc*₁ cannot be readily discerned from each other.¹⁶ However, recent genetic approaches successfully

produced asymmetric monomers to yield heterodimeric cytochrome *bc*₁ variants and provided data supporting intermonomer electron transfer.^{17–19}

Previously, we developed a two-plasmid genetic system to produce heterodimeric cytochrome *bc*₁ variants.^{19,20} The system used two independently expressed *petABC* operons carried by two plasmids of different replicons, coharbored by a cell lacking its endogenous cytochrome *bc*₁. Each plasmid carried a differently mutated and epitope-tagged cytochrome *b* and produced homodimeric and heterodimeric variants in the same cell. By selective inactivation of the Q_o site of one monomer and the Q_i site of the other monomer, evidence was obtained for the occurrence of intermonomer electron transfer between the *b*_L hemes of cytochrome *bc*₁.¹⁹ In this case, QH2 oxidation at the Q_o site was restricted using the cyt *b* Y147A mutation, which abolishes reduction of the low-potential chain (hemes *b*_L and *b*_H) of the enzyme.²¹ Similarly, the Q_i site was also disabled by the cyt *b* H212N mutation, which causes loss of heme *b*_H.²² Strains that produced only a homodimeric mutant cytochrome *bc*₁ were unable to grow photosynthetically (Ps~) as they produced inactive homodimers. In contrast, cells producing both homodimeric and heterodimeric cytochrome *bc*₁ variants exhibited slow Ps growth (Ps^{+/-}) compared to that of a wild-type strain and contained partially active cytochrome *bc*₁ equated with the heterodimeric variants.¹⁹ Time-resolved, light-activated single-turnover kinetics showed that intermolecular *b*_L-*b*_L-*b*_H heme electron transfer occurred in membranes from these cells at a rate slower (in the presence of the Q_i site inhibitor antimycin) than the rate of intramonomer *b*_L-*b*_H heme electron transfer seen in a wild-type enzyme under similar conditions.¹⁹ We also observed that strains carrying the two-plasmid system formed rare (~10⁻⁴) large Ps⁺ colonies among a population of predominantly small Ps^{+/-} colonies.^{19,20}

In our ongoing work, we characterized extensively both genetic and biochemical properties of the two-plasmid system that produces heterodimeric cytochrome *bc*₁. First, in the preceding paper (DOI: 10.1021/bi400560p), we addressed the molecular basis of the genetic rearrangements that occur when two identical plasmids (i.e., the same replicon) are used. We found that the large Ps⁺ colonies contained co-integrand plasmids predominantly formed via RecA-mediated recombination between the initial plasmids, and yielded increased amounts of active heterodimers, and better Ps growth [preceding paper (DOI: 10.1021/bi400560p)]. The co-integrand plasmids faithfully carried both the initial cytochrome *b* mutations and their associated epitope tags and reliably produced heterodimeric cytochrome *bc*₁ variants [preceding paper (DOI: 10.1021/bi400560p)]. Second, using this improved system with a set of Q_o and Q_i site mutations different from those used previously,¹⁹ we produced a novel heterodimeric cytochrome *bc*₁ (Figure 1) that supported efficient Ps⁺ growth and exhibited intermonomer reverse electron transfer among all four *b* hemes of cytochrome *bc*₁. This strain allowed large-scale purification of inactive homodimeric and active heterodimeric variants from the same cells. Analysis of purified proteins by mass spectrometry showed that they carried the expected cytochrome *b* mutations and their associated epitope tags. We conclude that the two-plasmid system produces reliably heterodimeric cytochrome *bc*₁ variants that support Ps (cytochrome *bc*₁-dependent) growth. Available data indicate that intermonomer reverse electron transfer occurs among the *b*_H, *b*_L, *b*_L, and *b*_H hemes of a dimeric enzyme, consistent with the heterodimeric Q cycle model. These findings are

discussed in terms of light-activated transient cytochrome *b* and *c* redox kinetics and in the context of the mechanism of function of cytochrome *bc*₁.

Materials and Methods

Bacterial Strains and Growth Conditions

All *R. capsulatus* strains harboring the plasmids that express the cytochrome *bc*₁ mutants were derivatives of strain MT-RBC1 [(*petABC::spe*)] or BK-RBC1 [(*petABC::spe*) (*recA*)] [preceding paper (DOI: 10.1021/bi400560p)] carrying a complete chromosomal deletion of *petABC* in a RecA⁺ or RecA⁻ background, respectively. They were grown in liquid or solid enriched (MPYE) medium, supplemented with antibiotics as appropriate [10 µg/mL kanamycin (Kan), 2.5 µg/mL tetracycline (Tet) and 10 µg/mL spectinomycin] under either Res (semiaerobic and dark) or Ps (photoheterotrophic and light) conditions at 35 °C, as described previously.²³ For Res growth, 1 L cultures in 2 L flasks were used. Plates were placed either in a dark incubator (Res) or in anaerobic jars with gas packs generating H₂ and CO₂ (Becton Dickinson Inc.) in temperature-controlled Percival light incubators (Ps).

Escherichia coli strains harboring the plasmids used were derived from HB101 [F⁻ (*gpt-proA*)62 *araC14 leuB6*(Am) *glnV44*(AS) *galK2*(Oc) *lacY1* (*mcrC-mrr*) *rpsL20*(Str^r) *xylA5 mtl-1 thi-1*] and grown on Luria-Bertani medium containing ampicillin, Kan, or Tet (100, 50, or 12.5 µg/mL, respectively) as appropriate.⁴ *R. capsulatus* strains coharboring two plasmids with the same type (*incQ/P4*) of replicon were obtained via triparental matings as described previously and as in the preceding paper (DOI: 10.1021/bi400560p). Strains coharboring two plasmids were maintained using half amounts of Kan and Tet, normally used for selection, and as a precautionary measure, large cultures were subjected to short periods of growth (~24 h) as described previously.¹⁹ Under these conditions, large Ps⁺ colonies were observed at frequencies of $\lesssim 10^{-4}$ in the RecA⁺ and RecA⁻ backgrounds with strains harboring two plasmids. Cultures that occasionally yielded more than ~0.01% large Ps⁺ clones were discarded.

Molecular Genetic and Biochemical Techniques

Molecular genetic techniques were performed using standard procedures, as described in detail in the preceding paper (DOI: 10.1021/bi400560p). Intracytoplasmic (chromatophore) membranes were obtained from frozen washed cells after two passages through a French press, as described previously.²⁵ Protein concentrations were determined using the bicinchoninic acid method²⁶ with bovine serum albumin as a standard. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) (12.5%) was conducted as described in ref 27, and prior to being loaded, samples were solubilized by incubation for 10 min at room temperature in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 0.1 M dithiothreitol, 25% glycerol, and 0.01% bromophenol blue. Immunoblot analyses were conducted as described in ref 19 using polyclonal antibodies against *R. capsulatus* cytochrome *b* or monoclonal anti-Flag (Sigma Inc.) and anti-Strep (Novagen Inc.) antibodies. Steady-state cytochrome *bc*₁ activity was measured using decylbenzohydroquinone (DBH₂) as an electron donor and horse heart cytochrome *c* as an electron acceptor at 25 °C.⁵ The reaction was initiated by enzyme addition and monitored at 550 nm for 1 min, and the portion of the initial rate that

was famoxadone sensitive was taken as the enzyme activity. *R. capsulatus* cytochrome *bc*₁ was purified and stored at -80 °C as described in ref 19.

Spectroscopic Techniques

Optical spectra were recorded on a Cary 60 spectrophotometer (Agilent Technologies Inc.). Absorption difference spectra for the *c*- and *b*-type cytochromes were obtained using chromatophore membranes (0.3 mg of total protein/mL), oxidized with potassium ferricyanide, and reduced with sodium ascorbate or sodium dithionite, as appropriate. EPR measurements were performed on a Bruker Elexsys E500 spectrometer. X-Band EPR spectra were recorded using a standard Bruker cavity (ER 4102ST) fitted to a helium flow cryostat (ESR900, Oxford Instruments). Spectrometer settings are indicated in figure legends.

Time-resolved, light-activated kinetic spectroscopy was performed on a dual-wavelength kinetic spectrophotometer with chromatophore membranes resuspended in 50 mM MOPS (pH 7.0) and 100 mM KCl buffer supplemented with 100 μ M ferricyanide (FeCN, 430 mV), 8 μ M DAD (260 mV), 6 μ M NQ (145 mV), 1 μ M PMS (80 mV), 1 μ M PES (50 mV), 6 μ M 2HNQ (-145 mV), and 6 μ M benzyl viologen (BV, -359 mV) as redox mediators and 2.5 μ M valinomycin as a membrane potential uncoupler.²⁸ The amounts of chromatophore membranes used in each assay were normalized to their reaction center (RC) content, as determined by measuring the flash-induced optical absorbance difference at 605–540 nm (E_h = 380 mV), and an extinction coefficient of 29.8 mM⁻¹ cm⁻¹. Transient cytochrome *c* re-reduction and cytochrome *b* reduction kinetics at an E_h of 100 mV, initiated by a short saturating flash (~8 μ s) from a xenon lamp, were followed at 550–540 and 560–570 nm, respectively. Antimycin, myxothiazol, and famoxadone were used at 10 μ M each, as needed.

Mass Spectrometry

Purified cytochrome *bc*₁ samples were subjected to in-solution digestion with chymotrypsin (Thermo Scientific Inc.) according to the manufacturer's recommendation. Repeat sample digestions were performed in the presence of methanol to facilitate cleavage of hydrophobic portions of cytochrome *b*, and as needed, cyanogen bromide (Sigma-Aldrich Inc.) cleavage was included to target the F144 position containing peptides according to the procedure described in refs 29 and 30. Digested samples were cleaned using ZipTip (Millipore Inc.), dried and resuspended in 5 μ L of 5% acetonitrile in 0.1% formic acid (buffer A), and analyzed with a nanospray LC-MS/MS Thermo LCQ Deca XP+ ion trap mass spectrometer coupled to a Thermo-Dionex LC Packings Ultimate Nano HPLC system controlled by Thermo Xcalibur version 2.0. A C18 nanocolumn (Thermo-Dionex, NAN-75-15-03-PM) was used to fractionate peptides, using a 90 min elution gradient (5 to 75% acetonitrile in 0.1% formic acid). The top three precursor ions were trapped and fragmented using dynamic exclusion to maximize the detection of unique peptides. Collected spectra were analyzed against the *R. capsulatus* protein database using Sequest and Thermo Bioworks version 3.3 with appropriate protease cleavage rules (F, W, Y, and L for chymotrypsin; M for CNBr) in full- and half-digestion modes, as needed. The computed results were filtered using standard values for X_{corr} (1.5, 2.0, and 2.5 for m/z +1, +2, and +3, respectively) and C_N (0.1), and all significant spectra were inspected manually to validate automatic assignments.

Chemicals

The cytochrome *bc*₁ inhibitors antimycin A and myxothiazol were purchased from Sigma-Aldrich, and famoxadone was obtained from DuPont Inc. Dodecyl maltoside was purchased from Anatrace Inc., and decylbenzoquinone (DBH) was from Sigma-Aldrich. DEAE-BioGel A was obtained from Bio-Rad.

Results

A New Heterodimeric Cytochrome *bc*₁ for Probing Intermonomer Electron Transfer between Its *b* Hemes

In this study, we produced a new heterodimeric cytochrome *bc*₁ using the improved [preceding paper (DOI: 10.1021/bi400560p)] two-plasmid genetic system. The previously produced heterodimeric cytochrome *bc*₁ (cyt *b*-S Y147A + cyt *b*-F H212N) could not be purified in an active form, because of its inherent instability induced by the absence of *b*_H heme. We thought a structurally less “perturbed” cytochrome *bc*₁ variant with intact cofactors would be more informative. Thus, the cyt *b* F144R³¹ and cyt *b* H217L³² mutations to inactivate the Q_o site in one monomer and the Q_i site in the other monomer, respectively, were chosen. The cyt *b* F144R mutation abolishes the transfer of an electron from QH₂ to heme *b*_L without affecting Q/QH₂ occupancy of the Q_o site. This Q_o site mutation is thought to form an ion pair with Q, conferring a unique EPR signature. The cyt *b* H217 residue is a highly conserved residue located in the vicinity of heme *b*_H and is involved in the stabilization of SQ at the Q_i site. Its substitution with leucine abolishes Q_i site catalytic activity without affecting enzyme assembly and stability.³² As before, the cytochrome *b* subunits were tagged with Strep and Flag epitopes to produce three different populations of cytochrome *bc*₁ variants in a given cell.¹⁹ These are the Q_o (cyt *b*-S F144R + cyt *b*-S F144R) and Q_i (cyt *b*-F H217L + cyt *b*-F H217L) site defective homodimers and the one-Q_o site and one-Q_i site defective heterodimer (cyt *b*-S F144R + cyt *b*-F H217L) (Figure 1).

Growth Properties of *R. capsulatus* Strains Producing Homodimeric and Heterodimeric Cytochrome *bc*₁ Variants

R. capsulatus strains harboring a single plasmid with wild-type *petABC* (pMTS1-S carrying a Strep epitope-tagged or pMTS1-F carrying a Flag epitope-tagged cytochrome *b*) were Ps⁺ and produced active homodimeric cytochrome *bc*₁, whereas those with a single cytochrome *b* mutation (cyt *b*-S F144R or cyt *b*-F H217L) were Ps[~] (not shown) and produced inactive, homodimeric cytochrome *bc*₁ [ref 19 and the preceding paper (DOI: 10.1021/bi400560p)]. The control strains harboring a two-plasmid system with epitope-tagged wild-type copies of *petABC* (cyt *b*-S + cyt *b*-F) were Ps⁺, and those carrying a two-plasmid system with two Q_o site mutations (cyt *b*-S F144R + cyt *b*-F T288S) were Ps[~] (data not shown) (the cyt *b* T288S mutation that inactivates the Q_o site was reported previously³³) (Figure 1) [preceding paper (DOI: 10.1021/bi400560p)]. Unlike the controls, both the RecA⁺ (MT-RBC1) and RecA⁻ (BK-RBC1) cells harboring the two-plasmid system with (cyt *b*-S F144R + cyt *b*-F H217L) mutations exhibited Ps⁺ growth (Figure 2A). As described in the preceding paper (DOI: 10.1021/bi400560p), the RecA⁻ strains grew slower under both Ps and Res conditions than the RecA⁺ strains. Cells carrying the two-plasmid system with (cyt *b*-S F144R + cyt *b*-F H217L) formed smaller Ps^{+/-} colonies than their corresponding wild-type parents. They

exhibited rare large Ps^+ colonies at frequencies of $<\sim 10^{-4}$ in RecA^+ and RecA^- backgrounds, and these colonies contained co-integrant plasmids that conserved faithfully the *cyt b* mutations and their associated epitope tags [preceding paper (DOI: 10.1021/bi400560p)]. This process is still not understood completely and deserves further study.

Biochemical Properties of *R. capsulatus* Strains Producing Homodimeric and Heterodimeric Cytochrome *bc*₁ Variants

SDS-PAGE and immunoblot analyses of appropriate strains using antibodies against cytochrome *b* or Strep or Flag epitopes indicated that cells harboring two plasmids exhibited both Strep- and Flag-tagged cytochrome *bc*₁ variants, similar to the corresponding single-epitope-tagged wild-type strains (Figure 2B). As the different epitope tag antibodies exhibit different affinities for their antigens, a better comparison of the amounts of cytochrome *bc*₁ produced in these strains was provided by optical spectroscopy. Chromatophore membranes of appropriate cells carrying the different plasmids showed that the optical spectra in the α region for the reduced cytochrome *b* at 560 nm and the high-potential cytochromes *c* at 550 nm were comparable to those of a wild-type parent (pMTS1) (Figure 2C). Thus, the mutation selected to inactivate the Q_0 and Q_i sites did not alter the biogenesis of cytochrome *bc*₁ and its cofactors to produce the expected homodimeric and heterodimeric variants.

Next, the cofactors of cytochrome *bc*₁ were examined by EPR spectroscopy (Figure 3). The EPR resonance lines at 3.78 and 3.43, corresponding to the g_z feature of oxidized b_L and b_H hemes, respectively, were detected in membranes of cells producing *cyt b*-S F144R + *cyt b*-F H217L homodimers as well as cells producing the heterodimeric variant (*cyt b*-S F144R + *cyt b*-F H217L) (Figure 3A). Although the amplitudes and shapes of the resonance lines were similar to those seen with a wild-type strain, the g_z values were different for the *cyt b*-S F144R and *cyt b*-F H217L variants. Chromatophore membranes containing the homodimeric *cyt b*-S F144R exhibited a wild-type-like cytochrome b_H g_z value centered at 3.43, whereas those of *cyt b*-F H217L had a g_z value centered at 3.49 (Figure 3A), probably caused by the local modifications of the heme b_H environment in this Q_i site mutation. Interestingly, chromatophore membranes of the strain carrying the (*cyt b*-S F144R + *cyt b*-F H217L) combination exhibited an intermediate g_z value at 3.46 (Figure 3A). The EPR spectra of cytochrome *bc*₁ [2Fe-2S] cluster g_y transition amplitudes were highly similar in different strains, indicating that the Fe-S protein was present in comparable amounts in all cases (Figure 3B). As expected, the shape and g_x values of the Fe-S protein [2Fe-2S] cluster signals were not identical in all mutants. Chromatophore membranes from cells producing the homodimeric *cyt b*-S F144R variant displayed a significantly narrowed and distorted [2Fe-2S] EPR spectrum, characterized by $g_x = 1.819$ and $g_y = 1.884$ features.³⁴ In contrast, the homodimeric *cyt b*-F H217L variant exhibited $g_x = 1.808$ and $g_y = 1.894$ features, which were identical to those seen with a wild-type cytochrome *bc*₁. Remarkably, membranes containing the heterodimeric (*cyt b*-S F144R + *cyt b*-F H217L) variant showed an intermediate EPR spectrum with characteristics associated with both cytochrome *b* mutations it carried. The [2Fe-2S] EPR spectrum displayed a slightly larger g_y resonance line at 1.892 and a larger g_x resonance line at 1.812 (Figure 3B). Overall, the EPR data established that these strains produced the expected mutant cytochrome *bc*₁ variants in comparable amounts.

Purification and Characterization of Epitope-Tagged Cytochrome *bc*₁ Variants

A two-step purification method, starting with anionic exchange (DEAE-BioGel), followed by epitope tag affinity chromatography, yielded large amounts of purified, mono-epitope-tagged homodimeric cyt *b*-S F144R and cyt *b*-F H217L, as well as double-epitope-tagged heterodimeric cytochrome *bc*₁ variants. SDS-PAGE and immunoblot analyses using specific cytochrome *b* and epitope tag antibodies (Figure 4A) and appropriate optical difference spectra (Figure 4B) established that the properties of purified, epitope-tagged homodimeric cytochrome *bc*₁ variants were comparable to those of their membrane-embedded versions. Next, a double-epitope-tagged heterodimeric cytochrome *bc*₁ produced by cells harboring the (cyt *b*-S F144R + cyt *b*-F H217L) mutations was purified as described in ref 19. DEAE-BioGel chromatography yielded partially purified and active [$\sim 0.6 \mu\text{mol}$ of cytochrome *c* min^{-1} (mg of total protein) $^{-1}$] cytochrome *bc*₁. These preparations were expected to contain two homodimeric (cyt *b*-S F144R and cyt *b*-F H217L) cytochrome *bc*₁ variants and one heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variant (Figure 4A,B). Two consecutive affinity chromatography steps (Flag followed by Strep binding columns, and Strep followed by Flag binding columns) were used to separate the homodimeric and heterodimeric variants. When affinity chromatography was initiated with a Strep binding column, flow-through and subsequent wash fractions contained only Flag-tagged materials, which were attributed to the homodimeric cyt *b*-F H217L variant (Figure 4A, lane 2). Elution fractions contained both Strep- and Flag-tagged material, attributed to the homodimeric cyt *b*-S F144R and the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) variants. These fractions were concentrated by ultrafiltration, loaded onto a Flag binding column, and washed to remove the homodimeric cyt *b*-S F144R variants (Figure 4A, lane 3). Subsequent elution from this column yielded the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ (Figure 4A, lane 4). Purified wild-type cytochrome *bc*₁ had a turnover activity of $\sim 57\text{--}64 \text{ s}^{-1}$ (micromoles of cytochrome *c* reduced per second per micromole of cytochrome *b*). In contrast, purified mutant homodimeric cyt *b*-S F144R and cyt *b*-F H217L variants had ~ 20 -fold lower turnover activities of $\sim 2.6\text{--}3.8 \text{ s}^{-1}$ (Figure 4C). The purified heterodimeric enzyme was active with a turnover activity of $\sim 15 \text{ s}^{-1}$, corresponding to $\sim 25\%$ of the turnover activity of a purified wild-type cytochrome *bc*₁ (Figure 4C).

Physical Evidence of the Production of a Heterodimeric *R. capsulatus* Cytochrome *bc*₁

Purified heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variants were analyzed by liquid chromatography and tandem mass spectrometry (nLC-MS/MS) to physically document the presence of both wild-type and mutant forms of epitope-tagged cytochrome *b*, as expected with a heterodimeric, asymmetrical cytochrome *bc*₁ (Figure 1). Special care was applied to optimize the digestion conditions and mass spectrometry parameters to detect the peptides encompassing positions 144 and 217 and the carboxyl terminus of cytochrome *b* (Materials and Methods), and these peptides are listed in Table 1. An exhaustive list of all peptides detected at similar levels using wild-type homodimeric cyt *b*-S F144R and cyt *b*-F H217L as well as mutant heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ samples and the related spectra are included in the Supporting Information (Table S1).

Homodimeric wild-type cytochrome *bc*₁ samples contained only the wild-type [M.VIYLLMMGTAF₁₄₄M.G] and [W.AFH₂₁₇TTGNNNPTGVEVR.R] peptides, which encompass positions 144 and 217 of cytochrome *b*, respectively. Similarly, homodimeric mutant cytochrome *bc*₁ samples contained only the [Y.LLMMGTAR₁₄₄MGY.L] or [FL₂₁₇TT-GNNNPTGVEVR.R] peptide in the case of cyt *b*-S F144R or cyt *b*-F H217L, respectively, with the Phe to Arg substitution at position 144 or His to Leu substitution at position 217 of cytochrome *b*. On the other hand, the heterodimeric cytochrome *bc*₁ samples yielded all peptides detected with both wild-type and homodimeric mutant samples (Table 1). In addition, analyses of the C-terminal peptides of cytochrome *b* revealed the presence of only the Strep [Y.GNPAEWSHPQFEK] or Flag [A.SIEEDFNSHYGNPAEDYKDDDDK] (underlined) tag in the case of the homodimeric samples, whereas both of these tags were detected with purified heterodimeric cytochrome *bc*₁, further confirming the SDS- PAGE and immunoblot data (Figure 4A). Overall, data indicated that the purified heterodimeric double-epitope-tagged and active cytochrome *bc*₁ variants had the cyt *b* F144R and cyt *b* H127L mutations, their native counterparts, and their associated epitope tags as expected.

Light-Activated, Single-Turnover Cytochrome *c* and Cytochrome *b* Reduction Kinetics of Homodimeric and Heterodimeric Cytochrome *bc*₁ Variants

The cytochrome *c* re-reduction and cytochrome *b* reduction kinetics were monitored as described previously¹⁹ by light-activated, time-resolved optical kinetic spectroscopy using chromatophore membranes derived from appropriate cells harboring cytochrome *bc*₁ variants in RecA⁺ (Figure 5) and RecA⁻ (Figure S1 of the Supporting Information) backgrounds. Typical cytochrome *c* re-reduction kinetics were observed with wild-type membranes in the presence and absence of inhibitors (Figure 5A, top row). Membranes derived from cells producing the cyt *b*-S F144R homodimer exhibited very slow cytochrome *c* re-reduction either in the absence or in the presence of any inhibitor, in agreement with the presence of an inactive cytochrome *bc*₁ with two defective Q_o sites (Figure 5A, second row). Interestingly, in the presence of famoxadone (a stigmatelin-like Q_o site inhibitor), the full extent of cytochrome *c* oxidation was not seen in this mutant,³⁴ suggesting that its Q_o site might be highly refractory to this inhibitor. On the other hand, in chromatophore membranes from cells harboring the cyt *b*-F H217L homodimers, some cytochrome *c* re-reduction kinetics were detected (Figure 5A, third row). As described previously, these kinetics were faster than those observed with cyt *b*-S F144R homodimers but slower than those with a wild-type cytochrome *bc*₁. Finally, cells producing the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) variant exhibited cytochrome *c* re-reduction kinetics that were much faster than those seen with the cyt *b*-F H217L homodimer but slower than those observed with a wild-type strain (Figure 5A, bottom row). As expected, chromatophore membranes containing the homodimeric cyt *b*-F H217L or heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) variants showed cytochrome *c* re-reduction kinetics that were myxothiazol or famoxadone sensitive, unlike those with the cyt *b*-S F144R variant.

The cytochrome *b* kinetics exhibited by these strains in the absence or presence of antimycin were very interesting (Figure 5B). First, typical cytochrome *b* kinetics with a rapid reduction followed by a rapid oxidation were seen with wild-type membranes in the absence of inhibitor (Figure 5B, top row). In contrast, the cytochrome *b* reduction—oxidation reaction

was not seen with membranes containing the homodimeric cyt *b*-S F144R mutant (Figure 5B, second row), as expected with a mutant lacking an active Q_o site.³⁴ In the case of the homodimeric cyt *b*-F H217L mutant, a partial cytochrome *b* reduction was observed in the absence of inhibitor (Figure 5, third row), reflecting an incomplete cytochrome *b* oxidation due to the absence of a stable Q/SQ at the Q_i site, as reported previously. Remarkably, the chromatophore membranes containing the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) variant exhibited cytochrome *b* kinetics with a slow transient oxidation readily observed on the time scale used (~50% oxidized after 150 ms vs the wild type, which is virtually 100% oxidized after 20 ms) (Figure 5B, bottom row). In this case, the initial rate of cytochrome *b* reduction was slower than that seen with a wild-type cytochrome *bc*₁, which exhibits a decay roughly complete after the reaction. Upon addition of antimycin A, which eliminates the transfer of an electron from heme *b*_H to the resident Q at the Q_i site, rapid and stable (on a time scale of 150 ms) cytochrome *b* reduction was seen with membranes derived from the wild type, the homodimeric cyt *b*-F H217L cytochrome *bc*₁ variant, and the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variant. As expected, these kinetics were not detected with the Q_o site defective cyt *b*-S F144R mutant. Moreover, in all cases, the cytochrome *b* reduction kinetics were sensitive to the Q_o inhibitors myxothiazol and famoxadone, confirming that the kinetics monitored indeed originated from Q_o site catalysis. Because both of the homodimeric variants are inactive with respect to the electron transfer processes examined, the slow reoxidation of cytochrome *b* reduction kinetics reflected the intrinsic properties of the heterodimeric (cyt *b*-F H217L + cyt *b*-S F144R) variant. The fast cytochrome *b* oxidation in a wild-type enzyme is generally attributed to the transfer of an electron from reduced cytochrome *b*_H to the Q_i site occupant Q or SQ (Figure 5, top row). Available data indicate that a major difference among the wild-type, homodimeric cyt *b*-F H217L, and heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variants is their Q_i site Q/SQ occupancy.³² We therefore attributed the slow cytochrome *b* reoxidation observed with the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variant to internal equilibration of electrons between all *b* hemes by “reverse” (i.e., among *b*_H, *b*_L, *b*_L, and *b*_H hemes) intermonomer electron transfer (Figure 5, bottom row). This slower electronic communication leading to the generation of SQ/QH₂ at the only active Q_i site of the heterodimeric enzyme provided sufficient turnover activity (~25% of that of the wild type) to sustain cyclic electron transport between the photochemical reaction center and cytochrome *bc*₁ to efficiently support Ps growth of *R. capsulatus*.

Discussion

In this study, we characterized a new heterodimeric cytochrome *bc*₁ variant using a two-plasmid system similar to that described in detail in the preceding paper (DOI: 10.1021/bi400560p). First, given the small distances that separate the cytochrome *b* mutations used and their associated epitope tags, we found that these strains do not undergo detectable genetic rearrangements that might lead to the loss or segregation of the genetic markers used. Thus, even if such events occur, their products are beyond the limits of detection of the biochemical analyses pursued. The robustness of the two-plasmid system, combined with

the precautions for avoiding selective growth conditions, and the use of shorter culture times established that the experimental data obtained are reliable.

Second, the new heterodimer carrying the (cyt *b*-S F144R + cyt *b*-F H217L) Q_o and Q_i site mutations had no effect on the structural stability of cytochrome *bc*₁. This enzyme contained all of its catalytic cofactors and was active under both *in vivo* and *in vitro* conditions. A strain carrying this new two-plasmid system supported the cytochrome *bc*₁-dependent Ps growth of *R. capsulatus* and showed interesting intermonomer electron transfer properties. Using the same cells, it was possible to conduct large-scale purification of homodimeric and hetero-dimeric cytochrome *bc*₁ variants, which exhibited ~5 and ~25% of wild-type cytochrome *bc*₁ turnover activity, respectively. Moreover, mass spectrometry analyses established that purified samples contained the cytochrome *b* mutations and their wild-type counterparts associated with appropriate epitope tags. Heterodimeric variants with linked cytochrome *b* subunits of cytochrome *b*-*bc*₁ enzymes have been reported previously.^{18,35} Previously, no active *R. capsulatus* heterodimeric native cytochrome *bc*₁ could be purified because the previously available heterodimeric (cyt *b*-S Y147A + cyt *b*-F H212N) variant lost its activity during purification.¹⁹ The new heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variant readily overcame this limitation.

A remarkable finding of this study was the electron transfer properties observed with the new heterodimeric cytochrome *bc*₁, which lacks a stable Q_i site occupant (Q/SQ) in one of its monomers. Strains producing heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variants exhibited unusual cytochrome *b* reduction and reoxidation kinetics at an ambient redox potential (*E*_h) of 100 mV, in the absence of inhibitors (Figure 5). Cytochrome *b* kinetics were clearly distinct from those usually seen with either a wild-type or a Q_i site defective homodimeric cyt *b*-F H217L cytochrome *bc*₁.³² With the heterodimeric enzyme, a single flash of light triggered a cytochrome *b* reduction (observed at a time range of up to ~10 ms), which preceded a slow reoxidation phase that took more than 150 ms to reach completion. At the same *E*_h and in the absence of an inhibitor, wild-type cytochrome *bc*₁ also exhibits biphasic (often poorly resolved on the millisecond time scale) cytochrome *b* reduction kinetics. However, these kinetics are more than an order of magnitude faster and roughly complete within the ~5–10 ms time span. As expected, with the homodimeric cyt *b*-F H217L mutant that lacks a stable Q/SQ at both its Q_i sites,³² in the absence of inhibitor at an *E*_h of 100 mV, a fast reduction but no reoxidation of cytochrome *b* was observed. The amplitude of this cytochrome *b* reduction corresponded roughly to one-half of that seen in the presence of antimycin and persisted for at least 150 ms. These observations support electron equilibration between hemes *b*_H and *b*_L of cytochrome *bc*₁, but because the *E*_m values of these hemes are highly affected by addition of antimycin in the cyt *b*-F H217L mutant, rigorous interpretation of the data remains difficult.³²

In the presence of antimycin, which eliminates the Q_i site residents (Q/SQ) and blocks rapid reoxidation of cytochrome *b* via the transfer of an electron from reduced heme *b*_H to Q/SQ, comparable cytochrome *b* reduction kinetics were observed with wild-type, homodimeric cyt *b*-F H217L, and heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variants. The major difference among these cytochrome *bc*₁ variants is the number of Q/SQ occupied active Q_i sites (i.e., two for the wild type, one for the heterodimeric mutant, and

none for the homodimeric mutant). We attributed the slow cytochrome *b* reoxidation kinetics seen only with the heterodimeric variant (Figure 5B) to the occurrence of electronic equilibration among all four *b* hemes, ultimately conveying electrons to the Q/SQ resident of the only active Q_i site of the enzyme. Provided that this interpretation is valid, reverse intermonomer electron transfer occurs to bridge the *b*_H, *b*_L, *b*_L, and *b*_H hemes to the active Q_i site present only on one of the two monomers. Qualitatively, the rate of this multistep electron transfer process, estimated by cytochrome *b* reoxidation rates, appears to be slower than intramonomer electron transfer that occurs from *b*_L and *b*_H hemes to the active Q_i on the same monomer (i.e., a wild-type enzyme) when possible, as seen by the cytochrome *b* reoxidation rates in the absence of an inhibitor and reduction rates in the presence of antimycin. These studies complemented the initial observations of direct intermonomer electron transfer that our group and others have reported.^{17–19} The findings rationalize why the heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variant has a slower turnover than a native enzyme and show that its catalytic efficiency is sufficient for physiological Ps growth of *R. capsulatus*.

Comparison of the intermonomer electron transfer events that are observed using the previously studied heterodimeric (cyt *b*-S Y147A + cyt *b*-F H212N) cytochrome *bc*₁ variant¹⁹ with those of the (cyt *b*-S F144R + cyt *b*-F H217L) variant is informative. Both of these heterodimeric variants were produced using a two-plasmid system in identical backgrounds together with inactive homodimers, and they had one defective Q_o site (i.e., cyt *b* F144R and cyt *b* Y147A mutations) on one monomer and one defective Q_i site (i.e., cyt *b*: H212N and cyt *b* H217L mutations) on the other monomer. However, the effects of these mutations on Q_o and Q_i site catalysis are different.^{1,22,31} Given that experimentally observed cytochrome *b* kinetics reflect multiple distinct steps of electron transfer, rigorous comparisons and interpretations are difficult. Nonetheless, in the absence of any inhibitor, the cytochrome *b* reduction and reoxidation kinetics observed with a heterodimer that has only one heme *b*_H coupled to an active Q_i site (cyt *b*-S Y147A + cyt *b*-F H212N)¹⁹ seem faster (i.e., not time-resolved) than those seen with the heterodimer (cyt *b*-S F144R + cyt *b*-F H217L) used here that has two *b*_H hemes, of which only one is coupled to an active Q_i site [i.e., time-resolved (Figure 5B, last row)]. In the presence of antimycin that inactivates all available Q_i sites, cytochrome *b* reduction kinetics seem faster with the latter heterodimer than the former, in agreement with the previously formulated thermodynamic considerations. This comparison indicates that in the case of a noninhibited heterodimeric enzyme lacking heme *b*_H on one monomer, the intermonomer electron transfer rate appears to be faster than what can be resolved on the millisecond time scale.

Finally, we note that the findings of this study are consistent with the “heterodimeric Q cycle” model, which postulates dismutation of the two SQ molecules formed at the Q_i sites to yield Q and QH₂ required to initiate a consecutive turnover of cyt *bc*₁. Interactions between the Q_o and Q_i sites within a given monomer and between the two monomers of cytochrome *bc*₁^{22,37} have been documented previously. Structural elements of cytochrome *b* such as formation of SQ at a Q site were proposed to act as a trigger for QH₂ oxidation at the cognate Q_o site with helix E and *ef* loop extension acting as a temporal “gate”. Mutants that perturb these structural elements, like the *b*_H heme ligands (i.e., cyt *b* H212N) or the Q_i

site occupancy (i.e., cyt *b* H217D, R, or L), also affect communications across membranes in cytochrome *bc*₁²² and its temporal gates. Consequently, heterodimeric variants engineered using these mutations to inactivate the Q_o and Q_i sites of a given monomer are expected to remain active, although at levels lower than that of the native enzyme, as indeed observed in ref 35.

In summary, this study provides strong evidence that the two-plasmid system appears to be a reliable genetic platform for producing inactive homodimeric and active heterodimeric cytochrome *bc*₁ variants with novel characteristics. Studies of asymmetric and yet active variants might uncover hidden properties of a dimeric cytochrome *bc*₁ and, eventually, provide an answer to whether the second QH₂ oxidation during the modified Q cycle mechanism occurs consecutively at the same Q_o site or at two different Q_o sites of two monomers. In addition, light-activated millisecond time scale kinetic spectroscopy using chromatophores, which so elegantly contributed to our understanding of the modified Q cycle mechanism for many years,¹¹ is now insufficient. A more complete understanding of how cytochrome *bc*₁ functions might be better achieved by studies of purified heterodimeric cytochrome *bc*₁ variants with microsecond time scale spectroscopy³⁸ and successful resolution of their three-dimensional structures.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This work was supported by National Institutes of Health Grant GM 38237 and the Division of Chemical Sciences, Geosciences and Biosciences, Office of Basic Energy Sciences of the U.S. Department of Energy, through Grant DE-FG02-91ER20052 to F.D.

References

1. Berry EA, Guergova-Kuras M, Huang LS, Crofts AR. Structure and function of cytochrome *bc* complexes. *Annu Rev Biochem.* 2000; 69:1005–1075. [PubMed: 10966481]
2. Mitchell P. Possible molecular mechanisms of the protonmotive function of cytochrome systems. *J Theor Biol.* 1976; 62:327–367. [PubMed: 186667]
3. Trumpower BL. The protonmotive Q cycle. Energy transduction by coupling of proton translocation to electron transfer by the cytochrome *bc*₁ complex. *J Biol Chem.* 1990; 265:11409–11412. [PubMed: 2164001]
4. Daldal F, Davidson E, Cheng S. Isolation of the structural genes for the Rieske Fe-S protein, cytochrome *b* and cytochrome *c*₁ all components of the ubiquinol:cytochrome *c*₂ oxidoreductase complex of *Rhodopseudomonas capsulata*. *J Mol Biol.* 1987; 195:1–12. [PubMed: 2821266]
5. Atta-Asafo-Adjei E, Daldal F. Size of the amino acid side chain at position 158 of cytochrome *b* is critical for an active cytochrome *bc*₁ complex and for photosynthetic growth of *Rhodobacter capsulatus*. *Proc Natl Acad Sci U S A.* 1991; 88:492–496. [PubMed: 1846443]
6. Berry, EA.; Lee, DW.; Huang, LS.; Daldal, F. Structural and Mutational Studies of the Cytochrome *bc*₁ Complex. In: Hunters, CN.; Daldal, F.; Thurnauer, MC.; Beatty, JT., editors. *The Purple Phototrophic Bacteria*. Springer; Dordrecht, The Netherlands: 2008. p. 425-450.
7. Xia D. Crystal structure of the cytochrome *bc*₁ complex from bovine heart mitochondria. *Science.* 1997; 277:60–66. [PubMed: 9204897]

8. Iwata S, Lee J, Okada K, Lee J, Iwata M, Rasmussen B, Link T, Ramaswamy S, Jap B. Complete structure of the 11-subunit bovine mitochondrial cytochrome *bc*₁ complex. *Science*. 1998; 281:64–71. [PubMed: 9651245]
9. Berry EA, Huang LS, Saechao LK, Pon NG, Valkova-Valchanova M, Daldal F. X-ray structure of *Rhodobacter capsulatus* cytochrome *bc*₁: Comparison with its mitochondrial and chloroplast counterparts. *Photosynth Res*. 2004; 81:251–275. [PubMed: 16034531]
10. Crofts AR, Meinhardt SW, Jones KR, Snozzi M. Theory of the quinone pool in the cyclic electron-transfer chain of *Rhodopseudomonas sphaeroides*: A modified Q-cycle mechanism. *Biochim Biophys Acta*. 1983; 723:202–218. [PubMed: 21494412]
11. Crofts AR. The Q-cycle: A personal perspective. *Photosynth Res*. 2004; 80:223–243. [PubMed: 16328823]
12. De Vries S, Albracht SP, Berden JA, Slater EC. The pathway of electrons through QH₂:cytochrome *c* oxidoreductase studied by pre-steady-state kinetics. *Biochim Biophys Acta*. 1982; 681:41–53. [PubMed: 6288082]
13. Gupta OA, Feniouk BA, Junge W, Mulikidjanian AY. The cytochrome *bc*₁ complex of *Rhodobacter capsulatus*: Ubiquinol oxidation in a dimeric Q-cycle? *FEBS Lett*. 1998; 431:291–296. [PubMed: 9708922]
14. Trumpower BL. A concerted, alternating sites mechanism of ubiquinol oxidation by the dimeric cytochrome *bc*₁ complex. *Biochim Biophys Acta*. 2002; 1555:166–173. [PubMed: 12206910]
15. Cooley JW, Lee DW, Daldal F. Across membrane communication between the Q_o and Q_i active sites of cytochrome *bc*₁. *Biochemistry*. 2009; 48:1888–1899. [PubMed: 19254042]
16. Cooley JW. A structural model for across membrane coupling between the Q_o and Q_i active sites of cytochrome *bc*₁. *Biochim Biophys Acta*. 2010; 1797:1842–1848. [PubMed: 20513347]
17. Castellani M, Covian R, Kleinschroth T, Anderka O, Ludwig B, Trumpower BL. Direct demonstration of half-of-the-sites reactivity in the dimeric cytochrome *bc*₁ complex: Enzyme with one inactive monomer is fully active but unable to activate the second ubiquinol oxidation site in response to ligand binding at the ubiquinone reduction site. *J Biol Chem*. 2010; 285:502–510. [PubMed: 19892700]
18. Swierczek M, Cieluch E, Sarewicz M, Borek A, Moser CC, Dutton PL, Osyczka A. An electronic bus bar lies in the core of cytochrome *bc*₁. *Science*. 2010; 329:451–454. [PubMed: 20651150]
19. Lanciano P, Lee DW, Yang H, Darrouzet E, Daldal F. Intermonomer electron transfer between the low-potential *b* hemes of cytochrome *bc*₁. *Biochemistry*. 2011; 50:1651–1663. [PubMed: 21261281]
20. Khalfaoui-Hassani B, Lanciano P, Lee DW, Darrouzet E, Daldal F. Recent advances in cytochrome *bc*₁: Intermonomer electronic communication? *FEBS Lett*. 2011; 586:617–621. [PubMed: 21878327]
21. Sariba AS, Ding H, Dutton PL, Daldal F. Tyrosine 147 of cytochrome *b* is required for efficient electron transfer at the ubihydroquinone oxidase site (Q_o) of the cytochrome *bc*₁ complex. *Biochemistry*. 1995; 34:16004–16012. [PubMed: 8519756]
22. Cooley JW, Ohnishi T, Daldal F. Binding dynamics at the quinone reduction (Q_i) site influence the equilibrium interactions of the iron sulfur protein and hydroquinone oxidation (Q_o) site of the cytochrome *bc*₁ complex. *Biochemistry*. 2005; 44:10520–10532. [PubMed: 16060661]
23. Darrouzet E, Valkova-Valchanova M, Daldal F. The [2Fe-2S] cluster E_m as an indicator of the iron-sulfur subunit position in the ubihydroquinone oxidation site of the cytochrome *bc*₁ complex. *J Biol Chem*. 2002; 277:3464–3470. [PubMed: 11707448]
24. Sambrook, J. *Molecular Cloning: A Laboratory Manual*. 3rd. Cold Spring Harbor Laboratory Press; Plainview, NY: 2001.
25. Gray KA, Davidson E, Daldal F. Mutagenesis of methionine-183 drastically affects the physicochemical properties of cytochrome *c*₁ of the *bc*₁ complex of *Rhodobacter capsulatus*. *Biochemistry*. 1992; 31:11864–11873. [PubMed: 1332776]
26. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. *Anal Biochem*. 1985; 150:76–85. [PubMed: 3843705]

27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*. 1970; 227:680–685. [PubMed: 5432063]
28. Valkova-Valchanova MB, Sariba AS, Gibney BR, Dutton PL, Daldal F. Isolation and characterization of a two-subunit cytochrome *b-c*₁ subcomplex from *Rhodobacter capsulatus* and reconstitution of its ubihydroquinone oxidation (Q_o) site with purified Fe-S protein subunit. *Biochemistry*. 1998; 37:16242–16251. [PubMed: 9819216]
29. Simpson, R. *Proteins and Proteomics*. Cold Spring Harbor Laboratory Press; Plainview, NY: 2003.
30. Onder O, Turkarslan S, Sun D, Daldal F. Overproduction or absence of the periplasmic protease DegP severely compromises bacterial growth in the absence of the dithiol:disulfide oxidoreductase DsbA. *Mol Cell Proteomics*. 2008; 7:875–890. [PubMed: 18174153]
31. Ding H, Daldal F, Dutton PL. Ion pair formation between basic residues at 144 of the Cyt *b* polypeptide and the ubiquinones at the Q_o site of the Cyt *bc*₁ complex. *Biochemistry*. 1995; 34:15997–16003. [PubMed: 8519755]
32. Gray KA, Dutton PL, Daldal F. Requirement of histidine 217 for ubiquinone reductase activity (Q_i site) in the cytochrome *bc*₁ complex. *Biochemistry*. 1994; 33:723–733. [PubMed: 8292600]
33. Darrouzet E, Daldal F. Protein-protein interactions between cytochrome *b* and the Fe-S protein subunits during QH₂ oxidation and large-scale domain movement in the *bc*₁ complex. *Biochemistry*. 2003; 42:1499–1507. [PubMed: 12578362]
34. Ding H, Moser CC, Robertson DE, Tokito MK, Daldal F, Dutton PL. Ubiquinone pair in the Q_o site central to the primary energy conversion reactions of cytochrome *bc*₁ complex. *Biochemistry*. 1995; 34:15979–15996. [PubMed: 8519754]
35. Czapla M, Borek A, Sarewicz M, Osyczka A. Enzymatic activities of isolated cytochrome *bc*₁-like complexes containing fused cytochrome *b* subunits with asymmetrically inactivated segments of electron transfer chains. *Biochemistry*. 2012; 51:829–835. [PubMed: 22233445]
36. Osyczka A, Moser CC, Daldal F, Dutton PL. Reversible redox energy coupling in electron transfer chains. *Nature*. 2004; 427:607–612. [PubMed: 14961113]
37. Covian R, Zwicker K, Rotsaert FA, Trumpower BL. Asymmetric and redox-specific binding of quinone and quinol at center N of the dimeric yeast cytochrome *bc*₁ complex. Consequences for semiquinone stabilization. *J Biol Chem*. 2007; 282:24198–24208. [PubMed: 17584742]
38. Havens J, Castellani M, Kleinschroth T, Ludwig B, Durham B, Millett F. Photoinitiated electron transfer within the *Paracoccus denitrificans* cytochrome *bc*₁ complex: Mobility of the iron–sulfur protein is modulated by the occupant of the Q_o site. *Biochemistry*. 2011; 50:10462–10472. [PubMed: 22026826]

Abbreviations

Q	quinone
QH₂	hydroquinone
Tet	tetracycline
Kan	kanamycin
Ps	photosynthesis
Res	respiration
DBH₂	decylbenzoquinone
S-	Strep epitope tag
F-	Flag epitope tag
EPR	electron paramagnetic resonance

Figure 1.

R. capsulatus system for studying intra- and intermonomer electron transfer in dimeric cytochrome bc_1 . Coexpression of a Kan^R plasmid carrying *petABC* with the *cyt b*-S F144R mutation and a Tet^R plasmid carrying *petABC* with the *cyt b*-F H217L mutation yields inactive homodimeric *cyt b*-S F144R (top left) and *cyt b*-F H217L (bottom left) as well as active heterodimeric (*cyt b*-F H217L + *cyt b*-S F144R) (top right) cytochrome bc_1 variants. An inactive heterodimer with two inactive Q_0 sites (*cyt b*-S F144R + *cyt b*-F T288S) used as a control is also shown (bottom right). Thick red dashed and thick blue solid arrows correspond to electron transfer to the high- and low-potential cofactor chains of cytochrome bc_1 , respectively. Inactive Q_0 or Q_i sites are indicated by X's, and the thin dotted line depicts the proposed reverse electron transfer between the hemes b_L and electron equilibration among all b hemes of the active heterodimeric cytochrome bc_1 .

Figure 2.

Growth phenotypes and biochemical properties of *R. capsulatus* strains producing heterodimeric cytochrome *bc*₁ variants. (A) Photosynthetic (Ps) and respiratory (Res) growth on enriched medium of *R. capsulatus* RecA⁺ (MT-RBC1) and RecA⁻ (BK-RBC1) strains harboring the two-plasmid system producing a heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variant. (B) SDS-PAGE and immunoblot analyses of Strep- and Flag-tagged cytochrome *b* subunits in chromatophore membranes of strains harboring different combinations of Kan^R and Tet^R plasmids producing homodimeric and heterodimeric cytochrome *bc*₁ variants. Approximately 10 μg of total membrane proteins was used, and cytochrome *b* contents were determined using polyclonal antibodies specific to *R. capsulatus* cytochrome *b* as well as commercially available monoclonal antibodies against the Strep (S) and Flag (F) epitope tags. (C) Optical redox difference spectra to reveal total *b*-type (dithionite-reduced minus ferricyanide-oxidized) (black) and *c*-type (ascorbate-reduced minus ferricyanide-oxidized) (red) cytochrome contents of chromatophore membranes (0.3 mg/mL) obtained from appropriate *R. capsulatus* strains grown by respiration in enriched medium.

Figure 3.

EPR characterization of *R. capsulatus* strains producing heterodimeric cytochrome bc_1 variants. (A) Low-spin heme EPR spectra of chromatophore membranes obtained from appropriate *R. capsulatus* strains grown by respiration in enriched medium. Spectra were recorded using partially oxidized (air-exposed, as-prepared) membranes derived from cells expressing cyt b -S F144R, cyt b -F H217L, and (cyt b -S F144R + cyt b -F H217L) cytochrome bc_1 variants. The following experimental conditions were used: temperature, 10 K; microwave power, 10 mW at 9.420 GHz; modulation amplitude, 10 G at 100 kHz, four scans. (B) [2Fe-2S] EPR spectra of ascorbate-reduced chromatophore membranes obtained from *R. capsulatus* strains listed in panel A and grown by respiration in enriched medium. The following experimental conditions were used: temperature, 20 K; microwave power, 2 mW at 9.416 GHz; modulation amplitude, 20 G at 100 kHz; one scan.

Figure 4.

Biochemical properties of purified *R. capsulatus* homo- and heterodimeric cytochrome *bc*₁ variants. The homodimeric cyt *b*-S F144R and cyt *b*-F H217L (F144R-S and H217L-F, respectively) and heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) (F144R-S + H217L-F) cytochrome *bc*₁ variants were partially purified from cells harboring the two-plasmid system carrying the indicated cytochrome *b* mutations by DEAE-BioGel chromatography and then applied to two consecutive affinity chromatography steps (Strep followed by Flag binding columns) to fractionate the homodimeric and heterodimeric cytochrome *bc*₁ variants. (A) Purified samples were subjected to SDS-PAGE and immunoblot analyses using 10 μ g of protein samples per lane, and the cytochrome *b* subunits were visualized using *R. capsulatus* specific polyclonal antibodies, as well as commercially available anti-Strep II or anti-Flag M2 monoclonal antibodies: lane 1, partially DEAE-BioGel purified cyt *bc*₁ containing both homo- and heterodimeric variants; lane 2, affinity-purified homodimeric cytochrome *bc*₁ variants tagged with the Strep epitope; lane 3, affinity-purified homodimeric cytochrome *bc*₁ variants tagged with the Flag epitope; lane 4, affinity-purified heterodimeric cytochrome *bc*₁ variants tagged both with Strep and Flag epitopes. (B) Optical redox difference spectra of the purified samples used in panel A together with a wild-type enzyme (pMTS1) to visualize their total *b*-type (dithionite-reduced minus ferricyanide-oxidized, black lines) and *c*-type (ascorbate-reduced minus ferricyanide-oxidized, red lines) cytochrome contents. (C) Steady-state cytochrome *bc*₁ activity of purified samples used in panel A together with a wild-type enzyme (pMTS1), measured by monitoring DBH₂:cytochrome *c* reduction at 550 nm on purified materials as described in Materials and Methods and the text.

Figure 5.

Light-induced, time-resolved cytochrome *b* reduction and cytochrome *c* re-reduction kinetics of various *R. capsulatus* strains. *R. capsulatus* strains producing wild-type (pMTS1), homodimeric cyt *b*-S F144R (F144R-S), homodimeric cyt *b*-F H217L (H217L-F), and heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) (F144R-S + H217L-F) cytochrome *bc*₁ variants were analyzed. In all cases, chromatophore membranes corresponding to an amount of reaction center equal to 0.30 μ M were resuspended in 50 mM MOPS buffer (pH 7.0) containing 100 mM KCl poised at an ambient redox potential (E_h) of 100 mV. (A) The cytochrome *c* re-reduction kinetics were monitored at 550 nm minus 540 nm, in the absence of inhibitor (black), in the presence of 10 μ M Q_i site inhibitor antimycin (blue), or in the presence of 10 μ M myxothiazol (yellow), which abolishes QH₂ oxidation at the Q_o site, or 10 μ M famoxadone (green), which abolishes the transfer of an electron from the [2Fe-2S] cluster heme *c*₁ by immobilizing the head domain of the Fe-S protein at the Q_o site: first row, wild-type pMTS1; second row, homodimeric cyt *b*-S F144R third row, homodimeric cyt *b*-F H217L fourth row, heterodimeric (F144R-S + H217L-F) cytochrome *bc*₁ variants. (B) The cytochrome *b* reduction kinetics were monitored at 560 nm minus 570 nm, in the absence of inhibitor (black), in the presence of 10 μ M Q_i site inhibitor antimycin (blue), in the presence of 10 μ M myxothiazol (yellow), or in the presence of 10 μ M famoxadone (green). In each case, the electron transfer events attributed to the kinetic traces are indicated by black arrows using a dimeric cytochrome *bc*₁ represented schematically in the central panel between panels A and B.

Table 1
Mass Spectrometry Analyses of Purified Cytochrome *bc*₁ Enzymes^a

Purified cytochrome <i>bc</i> ₁	Protease or treatment	Cytochrome <i>b</i> peptide	Peptide unique to
native homodimer (no tag control)	CNBr cleavage	M.VIYLLM*M*GTA <u>F</u> M@.G	F144 (wild type)
	chymotrypsin/aqueous	W.AFH <u>T</u> TGNNNPTGVEVR.R	H217 (wild type)
native-S homodimer (tag control)	chymotrypsin/60% methanol	F.NSHYGNPAEW. <u>S</u>	Strep tag
H217L-F homodimer (control)	CNBr cleavage	M.VIYLLM*M*GTA <u>F</u> M@.G	F144 (wild type)
	chymotrypsin/aqueous	<u>L</u> .TTGNNNPTGVEVR.R	H217L (mutant)
F144R-S homodimer (control)	CNBr cleavage	M.VIYLLM*M*GT <u>A</u> RM@.G	F144R (mutant)
F144R-S + H217L-F heterodimer	chymotrypsin/60% methanol	Y.GNPAEW <u>S</u> HPQFEK.	Strep tag
	chymotrypsin/aqueous	A.SIEEDFN <u>S</u> HYGNPAEDYK <u>D</u> DDDK.-	Flag tag
		W.AFH <u>T</u> TGNNNPTGVEVR.R	H217 (wild type)
		F. <u>L</u> TTGNNNPTGVEVR.R	H217L (mutant)
	CNBr cleavage	M.VIYLLM*M*GTA <u>F</u> M@.G	F144 (wild type)
		M.VIYLLM*M*GT <u>A</u> RM@.G	F144R (mutant)

^aPurified homodimeric (cyt *b*-S F144R and cyt *b*-F H217L) and heterodimeric (cyt *b*-S F144R + cyt *b*-F H217L) cytochrome *bc*₁ variants were analyzed by nLC—MS/MS spectrometry as described in Materials and Methods. Amino acid modifications and corresponding mass changes are indicated as follows: methionine oxidation (*, +16), homoserine formation (@, −30), and homoserine lactone formation (#, −48). The MS/MS spectra of the peptides listed are provided in Table S1 of the Supporting Information, together with a larger and redundant list of relevant peptides detected in these analyses.